

Substitute for form 1449A/PTO
**INFORMATION DISCLOSURE
 STATEMENT BY APPLICANT**
 (Use as many sheets as necessary)

Approved for use through 10/31/2002, OMB 651-0031
 US Patent & Trademark Office U.S. DEPARTMENT OF COMMERCE
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete if Known

Application Number	10/048,072
Filing Date	January 25, 2002
First Named Inventor	Franchini, Genoveffa
Group Art Unit	1648
Examiner Name	Parkin, Jeffrey

Sheet 1 of 1

Attorney Docket No: 1662.018US1

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
		BELSHE, R. , et al., "Support for the RV144 HIV vaccine trial.", <u>Science</u> , 305(5681), (July 9, 2004), 177-80	
		CORREA, R. , et al., "Functional patterns of HIV-1-specific CD4 T-cell responses in children are influenced by the extent of virus suppression and exposure", <u>AIDS</u> , 21(1), (2007), 23-30	
		GOMEZ, C. E., et al., "Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C", <u>Vaccine</u> , 25(11), (2007), 1969-92	
		GOMEZ, C. E., et al., "Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1IIIB Gag-Pol-Nef proteins of clade B", <u>Vaccine</u> , In Press, Corrected Proof, Available online 16 October 2006, (2006),	
		JACOBSON, J. M., et al., "Evidence that intermittent structured treatment interruption, but not immunization with ALVAC-HIV vCP1452, promotes host control of HIV replication: the results of AIDS Clinical Trials Group 5068", <u>J Infect Dis.</u> , 194(5), (2006), 623-32	
		JEFFERYS, R. , et al., "Outstanding questions on HIV vaccine trial", <u>Science</u> , 305(5681), (July 9, 2004), 180	
		JILEK, S. , et al., "CSF enrichment of highly differentiated CD8+ T cells in early multiple sclerosis", <u>Clinical Immunology</u> , 123(1), (2007), 105-113	
		KILBY, J. , et al., "A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024).", <u>The Journal of Infectious Diseases</u> , 194(12), (2006), 1672-6	
		PAL, R. , et al., "Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels.", <u>J Virol.</u> , 80(8), (Apr., 2006), 3732-42	
		PETERS, BARRY S., et al., "Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: Effects of dosage and route on safety and immunogenicity", <u>Vaccine</u> , 25(11), (2007), 2120-2127	
		TRINVUTHIPONG, C. , "Thailand's Prime-Boost HIV Vaccine Phase III", <u>Science</u> , 303(5660), (Feb. 13, 2004), 954-5	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1440)
 * EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 600. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional): Applicant is to place a check mark here if English language Translation is attached

* IDS fails to comply with 37 CFR 1.97 (d).